Gingival crevicular fluid and serum matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 levels in renal transplant patients undergoing different immunosuppressive therapy.
OBJECTIVE
We investigated gingival crevicular fluid (GCF) and serum matrix metalloproteinase-8 (MMP-8) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) levels from renal transplant patients receiving cyclosporine-A (CsA) and having gingival overgrowth (GO), from patients receiving CsA therapy and having no GO and patients receiving tacrolimus therapy.


METHODS
GCF samples were collected from sites with GO (GO+) and without GO (GO-) in CsA patients having GO; and GO- sites in CsA patients having no GO; sites from tacrolimus, gingivitis and healthy subjects. GCF and serum MMP-8 and TIMP-1 levels were determined by a time-resolved immunofluorometric assay (IFMA) and enzyme-linked immunosorbent assay.


RESULTS
GO+ sites in CsA patients having GO had elevated GCF MMP-8 levels compared with those of CsA patients having no GO, tacrolimus and healthy subjects (p<0.005), but these levels were similar to those of gingivitis. The GCF MMP-8 level was higher in GO+ compared with GO- sites in CsA patients having GO (p<0.05). GCF TIMP-1 levels were similar between groups. Tacrolimus patients had lower GCF MMP-8 levels than gingivitis (p<0.005), but levels similar to the healthy group.


CONCLUSIONS
These results show that CsA and tacrolimus therapy has no significant effect on GCF MMP-8 levels, and gingival inflammation seems to be the main reason for their elevations.
Emingil
Gülnur
G
Department of Periodontology, School of Dentistry, Ege University, Izmir, Turkey. gemingil@yahoo.com
Afacan
Beral
B
Tervahartiala
Taina
T
Töz
Hüseyin
H
Atilla
Gül
G
Sorsa
Timo
T
D000293:Adolescent; D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects*; D004812:Epidemiologic Methods; D005260:Female; D005883:Gingival Crevicular Fluid / Q000737:chemistry; D019214:Gingival Overgrowth / Q000139:chemically induced* / Q000000981:diagnostic imaging; D005891:Gingivitis / Q000000981:diagnostic imaging; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D020784:Matrix Metalloproteinase 8 / Q000097:blood*; D008875:Middle Aged; D011859:Radiography; D016559:Tacrolimus / Q000009:adverse effects; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000097:blood*
D007166:Immunosuppressive Agents; D019715:Tissue Inhibitor of Metalloproteinase-1; D016572:Cyclosporine; D020784:Matrix Metalloproteinase 8; D016559:Tacrolimus